Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins

What is this patent about?

’156 is related to the field of recombinant protein production in mammalian cell cultures, specifically focusing on the post-translational modification of glycoproteins. In the manufacturing of therapeutic monoclonal antibodies, the glycosylation profile—particularly the presence of high mannose glycans—is a critical quality attribute that influences serum clearance, effector functions, and overall efficacy. Traditional methods to control these sugar structures often rely on trial-and-error adjustments to media or physical culture parameters, which can inadvertently degrade cell productivity and yield.

The underlying idea behind ’156 is to achieve precise control over the glycan profile by genetically optimizing the cell’s internal N-glycosylation machinery rather than relying solely on external environmental factors. The invention identifies that by overexpressing specific enzymes and transporters responsible for processing sugar chains, the cell can more efficiently convert immature high mannose structures into complex glycoforms. This metabolic engineering approach allows for a significant reduction in undesirable species like Mannose 5 (Man5) without compromising the growth or titer of the production culture.

The claims of ’156 focus on a method for decreasing high mannose glycoform content by transfecting a mammalian host cell to overexpress specific proteins involved in the N-glycosylation pathway. The independent claim specifically targets the overexpression of N-acetyl-glucosaminyltransferase-1 (Mgat1), N-acetyl-glucosaminyltransferase-2 (Mgat2), or the UDP-Galactose transporter (Slc35a2), either individually or in combination. The method further requires a specific physiological trigger to transition the cells into a production state, defined as either a temperature shift or the induction of growth arrest via L-asparagine starvation.

In practice, the invention works by increasing the abundance of the enzymes that act as gatekeepers in the Golgi apparatus. By boosting the levels of Mgat1 and Mgat2, the cell can process branched glycans more rapidly, preventing the accumulation of high mannose intermediates. The implementation utilizes a biphasic culture strategy where cells are first grown to a high density and then shifted into a high-productivity, growth-arrested state. This shift is often supported by perfusion systems, such as alternating tangential flow, which maintain a stable nutrient environment while removing metabolic byproducts.

This approach differs from prior solutions by providing a targeted genetic fix for cell lines that are naturally prone to high mannose accumulation. While previous methods attempted to suppress high mannose through media additives or pH changes—which often led to inconsistent results and lower antibody titers—the use of metabolic engineering provides a robust and scalable mechanism for glycan control. By ensuring the enzymatic capacity of the cell matches its protein production rate, the invention allows for the manufacture of highly consistent therapeutic proteins with optimized pharmacokinetic properties.